Introduction: We report a case of relapse and refractory acute B-lymphoblastic leukemia (r/r B-ALL) apparently turned into acute myeloid leukemia, which is occasional and fatal during CAR-T treatment. There are still limited data to clarify the molecular mechanism of myeloid blast populations proliferation during CAR-T treatment. Case Presentation: A 21-year-old man with an established history of r/r B-ALL with a complex chromosome karyotype and renal extramedullary infiltration presented to our institution. He exhibited a rapid relapse with acute monocytic leukemia 19 days after CD19 CAR-T cell infusion with extensive infiltration of skin and brain. Salvage chemotherapy was ineffective, and he subsequently succumbed to the uncontrolled invasion and infiltration of leukemia cells and hemorrhage. RNA velocity analysis predicted that HSCs differentiated into GMPs and then GMPs differentiated into myeloid lineage cells. The ANXA1-FPR1/2 axis expression was significantly increased post-treatment, which promotes tumor cell proliferation, invasion, and angiogenesis. 6q deletion (6q-) was the common genetic abnormality across all cell populations, indicating that 6q- conferred a survival ability to HSCs during CAR-T cell therapy. Conclusions: This case demonstrates potential mechanisms of clone evolution molecular events that CD19 CAR-T cell infusion accelerated the existing myeloid lineage evolution via ANXA1-FPR1/2 axis expression from HSCs with 6q-. (Cyto-)genetic aberrations and/or pathways previously not included in the risk stratification of B-ALL might well be predictive for response and outcome in the era of immunotherapy.

1.
Maude
SL
,
Laetsch
TW
,
Buechner
J
,
Rives
S
,
Boyer
M
,
Bittencourt
H
, et al
.
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
.
N Engl J Med
.
2018
;
378
(
5
):
439
48
.
2.
Gardner
RA
,
Finney
O
,
Annesley
C
,
Brakke
H
,
Summers
C
,
Leger
K
, et al
.
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
.
Blood
.
2017
;
129
(
25
):
3322
31
.
3.
Park
JH
,
Riviere
I
,
Gonen
M
,
Wang
X
,
Senechal
B
,
Curran
KJ
, et al
.
Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
.
N Engl J Med
.
2018
;
378
(
5
):
449
59
.
4.
Rossi
JG
,
Bernasconi
AR
,
Alonso
CN
,
Rubio
PL
,
Gallego
MS
,
Carrara
CA
, et al
.
Lineage switch in childhood acute leukemia: an unusual event with poor outcome
.
Am J Hematol
.
2012
;
87
(
9
):
890
7
.
5.
Zheng
L
,
Li
L
,
Wang
B
,
Zhang
S
,
Fu
Z
,
Cheng
A
, et al
.
Annexin A1 affects tumor metastasis through epithelial-mesenchymal transition: a narrative review
.
Transl Cancer Res
.
2022
;
11
(
12
):
4416
33
.
6.
Markiewski
MM
,
Vadrevu
SK
,
Sharma
SK
,
Chintala
NK
,
Ghouse
S
,
Cho
JH
, et al
.
The ribosomal protein S19 suppresses antitumor immune responses via the complement C5a receptor 1
.
J Immunol
.
2017
;
198
(
7
):
2989
99
.
7.
Shah
NN
,
Fry
TJ
.
Mechanisms of resistance to CAR T cell therapy
.
Nat Rev Clin Oncol
.
2019
;
16
(
6
):
372
85
.
8.
Orlando
EJ
,
Han
X
,
Tribouley
C
,
Wood
PA
,
Leary
RJ
,
Riester
M
, et al
.
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
.
Nat Med
.
2018
;
24
(
10
):
1504
6
.
9.
Grupp
SA
,
Kalos
M
,
Barrett
D
,
Aplenc
R
,
Porter
DL
,
Rheingold
SR
, et al
.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
.
N Engl J Med
.
2013
;
368
(
16
):
1509
18
.
10.
Maude
SL
,
Frey
N
,
Shaw
PA
,
Aplenc
R
,
Barrett
DM
,
Bunin
NJ
, et al
.
Chimeric antigen receptor T cells for sustained remissions in leukemia
.
N Engl J Med
.
2014
;
371
(
16
):
1507
17
.
11.
Si Lim
SJ
,
Grupp
SA
,
DiNofia
AM
.
Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia
.
Pediatr Blood Cancer
.
2021
;
68
(
9
):
e29123
.
12.
Dourthe
ME
,
Rabian
F
,
Yakouben
K
,
Chevillon
F
,
Cabannes-Hamy
A
,
Mechinaud
F
, et al
.
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
.
Leukemia
.
2021
;
35
(
12
):
3383
93
.
13.
Schultz
LM
,
Baggott
C
,
Prabhu
S
,
Pacenta
HL
,
Phillips
CL
,
Rossoff
J
, et al
.
Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor Consortium report
.
J Clin Oncol
.
2022
;
40
(
9
):
945
55
.
14.
Lamble
AJ
,
Myers
RM
,
Taraseviciute
A
,
John
S
,
Yates
B
,
Steinberg
SM
, et al
.
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
.
Blood Adv
.
2023
;
7
(
4
):
575
85
.
15.
Rabilloud
T
,
Potier
D
,
Pankaew
S
,
Nozais
M
,
Loosveld
M
,
Payet-Bornet
D
.
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
.
Nat Commun
.
2021
;
12
(
1
):
865
.
16.
Schultz
LM
,
Eaton
A
,
Baggott
C
,
Rossoff
J
,
Prabhu
S
,
Keating
AK
, et al
.
Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia
.
J Clin Oncol
.
2023
;
41
(
2
):
354
63
.
17.
Jarosova
M
,
Hruba
M
,
Oltova
A
,
Plevova
K
,
Kruzova
L
,
Kriegova
E
, et al
.
Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients
.
Am J Hematol
.
2017
;
92
(
10
):
E604
7
.
18.
Forgeard
N
,
Baron
M
,
Caron
J
,
Boccon-Gibod
C
,
Krzisch
D
,
Guedes
N
, et al
.
Inflammation in Waldenstrom macroglobulinemia is associated with 6q deletion and need for treatment initiation
.
Haematologica
.
2022
;
107
(
11
):
2720
4
.
19.
Engwerda
A
,
Kerstjens-Frederikse
WS
,
Corsten-Janssen
N
,
Dijkhuizen
T
,
van Ravenswaaij-Arts
CMA
.
The phenotypic spectrum of terminal 6q deletions based on a large cohort derived from social media and literature: a prominent role for DLL1
.
Orphanet J Rare Dis
.
2023
;
18
(
1
):
59
.
20.
Backx
L
,
Fryns
JP
,
Marcelis
C
,
Devriendt
K
,
Vermeesch
J
,
Van Esch
H
.
Haploinsufficiency of the gene Quaking (QKI) is associated with the 6q terminal deletion syndrome
.
Am J Med Genet
.
2010
;
152A
(
2
):
319
26
.
21.
Chen
L
,
Sun
CY
,
An
BW
,
Yu
JM
,
Zhao
F
,
Zhang
C
, et al
.
[Clinical characteristics of patients with multiple myeloma harboring 6q deletion]
.
Zhonghua Xue Ye Xue Za Zhi
.
2021
;
42
(
8
):
642
5
.
You do not currently have access to this content.